Burcu DUYUR ÇAKIT, Hakan GENÇ, Barış NACIR, Secil PERVANE VURAL, Mehmet Onat ÇAKIT, Sühan TAŞKIN, Müyesser OKUMUŞ

POSTMENOPOZAL ROMATOİD ARTRİTLİ HASTALARDA BİFOSFONAT TEDAVİSİNİN HASTALIK AKTİVİTESİ ÜZERİNE ETKİSİ

GİRİŞ: Bifosfonat tedavileri, biyolojik ajanlara intoleransı veya kontreendike durumu olan romatoid artrit hastaları için sentetik hastalık modifiye edici ajanların etkisini tamamlayan ajanlar olabilir. Bu retrospektif çalışmanın amacı bifosfonat tedavisinin sentetik modifiye edici ajan kullanan romatoid artrit hastalarındaki hastalık aktivitesi üzerine etkisini incelemektir. MATERYAL VE METHOD: Veriler kliniğimizin romatoloji departmanındaki hasta kayıtlarının retrospektif olarak incelenmesi ile elde edilmiştir. Çalışma için, 45 yaş üstü ve ardışık yıllarda kemik mineral yoğunluğu değerlendirilen 207 hasta dosyası tarandı. Hastaların demografik bilgileri, ilaçları, hastalık süreleri, hastalığa yakalandıkları yaş, anti-siklik sitrullin peptit, romatoid faktör pozitifliği, hastalık aktivite skorları gibi bilgiler kayıt edildi. Kemik mineral dansitesi analizleri dual enerji x-ray absorptiometri ile yapıldı. Bir yıldır bifosfonat tedavisi alan 106 hasta (89 kadın, 17 erkek) grup1, bifosfonat tedavisi almayan 101 hasta (81 kadın, 20 erkek) ise grup 2 olarak ayrıldı. BULGULAR: Grup 1 hastaların yaş ortalaması 65.02 ± 11.14 yıl iken, grup 2 hastalarınki 63.64±9.1 yıl idi (p>0.05). Gruplar arasında yaş, cinsiyet, hastalık süresi açısından istatistiksel olarak anlamlı fark yoktu. Gruplar arasında kullanılan hastalık modifiye edici ilaç tipleri ve dozajları arasında istatistiksel olarak anlamlı fark yoktu (p>0.05), fakat grup 1'de prednizolon kullanımı grup 2'den daha fazlaydı (p

THE EFFECTS OF BISPHOSPONATES THERAPY IN PATIENTS WITH POSTMENAPOUSAL RHEUMATOID ARTHRITIS

INTRODUCTION: Bisphosphonates therapy may be potentialadjunctive therapy agents of synthetic disease modifying antirheumaticdrugs in rheumatoid arthitis patients who have contraindications andwho are intolerant to biologics. The aim of this retrospective study wasto evaluate the effects of adjunctive Bisphosphonates on disease activityof our patients with rheumatoid arthitis who underwent the syntheticdisease modifying antirheumatic drugs therapy.MATERIAL AND METHOD: Retrospective data were collectedfrom patient records of our Rheumatology department outpatientclinic. Files of 207 patients who are over 45 years old and whose bonemineral density were evaluated in the previous year were screened forthe study. Patients demographics, medications, disease duration, theage of disease onset, anti-Cyclic Citrullinated Peptid, Rheumatoid factorpositivily, Disease activity scores positivity were recorded. Bone mineraldensitometry analyses were performed in patients by Dual EnergyX-ray Absorptiometry. 106 patients (89 women, 17 men) who receivedbisphosponates therapy for 1 year constituted group1 and 101 patients (81women 20 men) who did not receive bisphosponates constituted group 2.RESULTS: The mean age of group 1 was 65.02 ± 11.14 years and group2 was 63.64±9.1 years (p > 0.05). There was no statistically significantdifference between groups in terms of age, gender and disease durationparameters. There were no statistically significant difference according todisease modifying antirheumatic drugs type and dosages between groups(p > 0.05) but in group 1, prednisolone users were more than group 2(p < 0.001). The mean tender joint count changes were -0.64±0.63 ingroup 1 and 0.42±0.62 in group 2 (p

PDF

___

Kapetanovic MC, Lindqvist E, Nilsson JÅ, Geborek P, Saxne T, Eberhardt K. Development of functional impairment and disability in rheumatoid arthritis patients followed for 20 years: relation to disease activity, joint damage, and comorbidity. Arthritis Care Res (Hoboken). 2015 Mar;67(3):340-8
Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, Romas E. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004;50:2338-46.
Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O’Connor PJ, Grainger AJ, Emery P. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rhaumatoid arthritis. Arthritis Rheum 2006;54(5):1410-14.
Goldring SR, Gravallese EM. Bisphosphonates: environmental protection for the joint Arthritis Rheum. 2004 Jul;50(7):2044-7.
Breuil V, Euller-Ziegler L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 2006;73(4):349-54.
Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol. 2004;16(4):419-27.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology / European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-1588.
Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6.
Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11.
Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989;48(5):396-9.
Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 2003 Mar;30(3):474-9.
Cantatore FP, Acquista CA, Pipitone V.Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999;26(11):2318-23.
Toussirot E, Wendling D. Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. Expert Opin Pharmacother 2005;6(1):35-43.
Harada H, Katsumata T, Nakayama T, Nanaka T, . Inflamm Res. Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis. Inflamm Res 2004;53(2):45-52.
Ozgonenel L, Cetin E, Tutun S, Tonbaklar P, Aral H, Guvenen G. The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis. Clin Rheumatol 2010 May;29(5):473-7.
Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, Toussirot E. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003;132(1):158-62.
Szekanecz Z, Koch AE. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007;3:635-43.
Kawabata A, Naoyuki N, Hironaka Y, Ishiki T, Matsunami M, Sekiguchi F. Antiallodynic effect of etidronate, a bisphosphonate, in rats with adjuvant-induced arthritis: Involvement of ATPsensitive K+ channels. Neuropharmacology 2006;51:182-190.
Forbslad D’elia H, Larsen A, Waltbrand E, Kvist G, Mellstrom D,Saxne T et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalized osteoporosis. Ann Rheum Dis 2003;62:617-23.
Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, Skeith KJ, Aaron SL, Homik J, Davis P, Sholter D, Russell AS. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46(3):766-73.
Soejima M, Kawaguchi Y, Hara M, Saito S, Kamatani N, Yamanaka H. Therapeutic effects of alendronate on bone erosion and atrophy in a patient with rheumatoid arthritis and hepatitis C virus infection. J Rheumatol. 2008;35(11):2284-6.
Goh L, Samanta A. A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 2009;29(10):1123-35.
Slobodin G, Rosner I, Rimar D, Boulman N, Rozenbaum M, Odeh M. The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis. Clin Rheumatol 2010;29:793- 794.